<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04191824</url>
  </required_header>
  <id_info>
    <org_study_id>PRO00102997</org_study_id>
    <nct_id>NCT04191824</nct_id>
  </id_info>
  <brief_title>Genetic Testing to Understand and Address Renal Disease Disparities Across the United States</brief_title>
  <acronym>GUARDD-US</acronym>
  <official_title>Genetic Testing to Understand and Address Renal Disease Disparities Across the United States</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aim is to determine the effect of participant and provider knowledge of a
      positive APOL1 status and accompanying guideline based clinical decision support (CDS) on
      blood pressure management on change in systolic blood pressure (SBP) from baseline to 3
      months after randomization among the APOL1 positive participants. Secondary aims are to:

        1. Determine the effect of participant and provider knowledge of a positive APOL1 status on
           the probability of appropriate CKD diagnosis.

        2. Determine the effect of participant and provider knowledge of a positive APOL1 status on
           the probability of receiving a urine microalbumin/creatinine testing and ACE-I/ARB
           prescription based on results of the urine microalbumin level.

        3. Explore cost effectiveness, mediators, moderators, psychobehavioral impact of results
           disclosure on participants, and effects of participant and provider knowledge of APOL1
           status on provider treatment recommendations.

      PGX Substudy

      In addition, GUARDD-US will include a substudy to determine the effect of knowledge of
      genetic test results that predict efficacy of various antihypertensive medications on change
      in SBP from baseline to 3 months in APOL1 negative individuals.

      Approximately 5,435 participants of African ancestry age 18-70 with hypertension that either:
      1) do not have diabetes and do not have CKD, or 2) have CKD. Participants with diabetes may
      be included as long as they also have CKD.

      Population for Main Study:

      Participants from Randomized Population (above) who test positive for APOL1

      Population for PGx Substudy:

      Participants from Randomized Population (above) randomized to Intervention and who test
      negative for APOL1

      Main Study Analyses:

        -  To determine the effect of participant and provider knowledge of a positive APOL1 status
           on SBP, we will compare the change in SBP from baseline to 3 months of the Intervention
           - APOL1 positive group to the change in SBP from baseline to 3 months of the Control -
           APOL1 positive group using a two sided Mann Whitney test, as appropriate, with a
           two-sided type I error of 0.05.

        -  The effect of knowledge of a positive APOL1 status on all secondary endpoints will be
           compared between Intervention - APOL1 positives to Control - APOL1 positives with the
           proportion difference test.

        -  Additional analyses will include analysis of time trends in SBP, subset analyses, and
           exploratory analyses of cost effectiveness, mediators, moderators, psychobehavioral
           impact of results disclosure on participants, and effects of knowledge of APOL1 status
           on provider treatment recommendations.

      Substudy Analyses:

      All primary and secondary endpoint analyses conducted for the APOL1 main study will be
      repeated for the PGx substudy focusing on differences in outcomes between APOL1 negative
      individuals with immediate PGx ROR (PGx Intervention) and APOL1 negative individuals with
      delayed PGx ROR (PGx Control).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2020</start_date>
  <completion_date type="Anticipated">July 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 15, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Immediate versus delayed return of Apolipoprotein L1 (APOL1) gene testing results to provider and participant.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in systolic blood pressure from baseline to 3 months</measure>
    <time_frame>Baseline to 3 month study visit</time_frame>
    <description>Change in systolic blood pressure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in urine microalbuminuria/proteinuria</measure>
    <time_frame>From baseline to 6 months</time_frame>
    <description>Change in urine microalbuminuria/proteinuria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Appropriate order of microalbuminuria/proteinuria tests</measure>
    <time_frame>baseline to 6 months</time_frame>
    <description>Appropriate order of microalbuminuria/proteinuria tests</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in appropriate diagnosis for stage 3 CKD</measure>
    <time_frame>baseline to 6 months</time_frame>
    <description>Change in appropriate diagnosis for stage 3 CKD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Appropriate diagnosis of CKD stage 3 and above</measure>
    <time_frame>baseline to 6 months</time_frame>
    <description>Appropriate diagnosis of CKD stage 3 and above</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in appropriate diagnosis for any stage CKD</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>Change in appropriate diagnosis for any stage CKD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Appropriate diagnosis of all stage CKD</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>Appropriate diagnosis of all stage CKD</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">5435</enrollment>
  <condition>Renal Disease</condition>
  <arm_group>
    <arm_group_label>Immediate Return of Results</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Immediate return of results to inform participant of APOL1 status (either positive or negative).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Delayed Return of Results</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Delayed return of results of APOL1 status (either positive or negative) after the completion of the 6 month final study visit.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>APOL1 status</intervention_name>
    <description>Participants will be randomized to immediate versus delayed return of results for positive or negative APOL1 status.</description>
    <arm_group_label>Delayed Return of Results</arm_group_label>
    <arm_group_label>Immediate Return of Results</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  African American/Black

          -  English Speaking

          -  Age 18-70 years

          -  Have diagnosis of hypertension

        Diagnosis of hypertension is defined by either:

          -  ICD10 diagnosis codes (i.e., I10; I11.x; I12.x; I13.x; I16.x) OR

          -  On active antihypertensive therapy for indication of hypertension OR

          -  Having systolic blood pressure of 140 mm Hg or greater in at least 2 of the last 3
             consecutive recorded values in the EHR OR

          -  Having hypertension in the patient's medical record problem list

               -  Have been seen at ≥1 time in past year at a participating primary care site

               -  Either: 1) do not have diabetes and do not have CKD, or 2) have CKD;

        Participants with diabetes may be included as long as they also have CKD.

          -  CKD is defined by either:

             1) ICD10 codes (i.e., N18.x; E08.22; E09.22; E10.22; E11.22;E13.22 (exclude Z94.0;
             N18.6; Z99.2)) OR

          -  15 ≤ eGFR ≤ 60 ml/min for 2 time periods ≥ 3 months

          -  Diabetes is defined by:

          -  HbA1c ≥ 6.5 at least one time in the last year OR

          -  ICD10 diagnosis codes (see Appendix A) OR

          -  Having diabetes in the patient's medical record problem list

        Exclusion Criteria:

          -  Have diabetes, but no CKD.

          -  Are currently on dialysis (ICD 10 codes N18.6, Z99.2 and Z94.0)

          -  Have ESRD (eGFR&lt;15 ml/min)

          -  Have a terminal illness

          -  Have patient-reported known pregnancy at time of enrollment

          -  Have had a liver, kidney, or bone marrow transplant

          -  Too cognitively impaired to provide informed consent and/or complete the study
             protocol

          -  Institutionalized or too ill to participate (i.e. incarcerated, psychiatric or nursing
             home facility)

          -  Plan to move out of the area within 6 months of enrollment

          -  Not a current patient seeing a provider who cares for their hypertension (i.e., family
             medicine, internal medicine, nephrology, HIV provider, cardiology, hypertension
             specialists) at a participating site

          -  Previously participated in the GUARDD pilot study OR have previously undergone APOL1
             testing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hrishikesh Chakraborty</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Teji Rakhra-Burris</last_name>
    <phone>919-684-9849</phone>
    <email>teji.rb@duke.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Florida (Gainesville and Jacksonville)</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Erica Elwood</last_name>
      <phone>352-273-6007</phone>
      <email>erica.elwood@cop.ufl.edu</email>
    </contact>
    <investigator>
      <last_name>Rhonda Cooper-DeHoff, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Sheryl Lynch</last_name>
      <phone>317-274-2765</phone>
      <email>slynch@iu.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Eadon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center New Orleans</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Brianne Voros</last_name>
      <phone>504-702-3143</phone>
      <email>Brianne.Voros@lcmchealth.org</email>
    </contact>
    <investigator>
      <last_name>Jyotsna Fuloria, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Michelle Ramos</last_name>
      <phone>212-659-9571</phone>
      <email>michelle.ramos@mountsinai.org</email>
    </contact>
    <investigator>
      <last_name>Carol Horowitz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Institute for Family Health</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10035</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Nandini Shroff</last_name>
      <phone>212-633-0800</phone>
      <phone_ext>1363</phone_ext>
      <email>Nshroff@institute.org</email>
    </contact>
    <investigator>
      <last_name>Neil Calman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southeastern Healthcare</name>
      <address>
        <city>Lumberton</city>
        <state>North Carolina</state>
        <zip>28358</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Lori Dove</last_name>
      <phone>910-674-9526</phone>
      <email>dove01@srmc.org</email>
    </contact>
    <investigator>
      <last_name>Joseph Roberts, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Meharry Medical College</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37208</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Rajbir Singh</last_name>
      <phone>615-327-6204</phone>
      <email>henry.h.ong@vumc.org</email>
    </contact>
    <investigator>
      <last_name>Rajbir Singh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Henry Ong</last_name>
      <phone>615-322-5000</phone>
      <email>henry.h.ong@vumc.org</email>
    </contact>
    <investigator>
      <last_name>Kerri Cavanaugh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor Research Institute</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75210</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Aisha Montgomery</last_name>
      <phone>214-865-3071</phone>
      <email>Aisha.Montgomery@BSWHealth.org</email>
    </contact>
    <investigator>
      <last_name>Heather Kitzman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>December 5, 2019</study_first_submitted>
  <study_first_submitted_qc>December 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 10, 2019</study_first_posted>
  <last_update_submitted>July 10, 2020</last_update_submitted>
  <last_update_submitted_qc>July 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

